AU2019391329B2 - New crystalline forms of a MCL-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them. - Google Patents
New crystalline forms of a MCL-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them. Download PDFInfo
- Publication number
- AU2019391329B2 AU2019391329B2 AU2019391329A AU2019391329A AU2019391329B2 AU 2019391329 B2 AU2019391329 B2 AU 2019391329B2 AU 2019391329 A AU2019391329 A AU 2019391329A AU 2019391329 A AU2019391329 A AU 2019391329A AU 2019391329 B2 AU2019391329 B2 AU 2019391329B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- crystalline form
- cancer
- theta
- expressed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306634.9 | 2018-12-06 | ||
| EP18306634 | 2018-12-06 | ||
| PCT/EP2019/083773 WO2020115183A1 (en) | 2018-12-06 | 2019-12-05 | New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019391329A1 AU2019391329A1 (en) | 2021-07-01 |
| AU2019391329B2 true AU2019391329B2 (en) | 2024-09-26 |
Family
ID=64665802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019391329A Active AU2019391329B2 (en) | 2018-12-06 | 2019-12-05 | New crystalline forms of a MCL-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US12129261B2 (https=) |
| EP (1) | EP3891156B1 (https=) |
| JP (1) | JP7649241B2 (https=) |
| KR (1) | KR102855345B1 (https=) |
| CN (1) | CN113166169A (https=) |
| AR (1) | AR117255A1 (https=) |
| AU (1) | AU2019391329B2 (https=) |
| BR (1) | BR112021010072A2 (https=) |
| CA (1) | CA3121363A1 (https=) |
| DK (1) | DK3891156T3 (https=) |
| EA (1) | EA202191534A1 (https=) |
| ES (1) | ES2971258T3 (https=) |
| FI (1) | FI3891156T3 (https=) |
| HR (1) | HRP20240211T1 (https=) |
| HU (1) | HUE065266T2 (https=) |
| IL (1) | IL283656B2 (https=) |
| LT (1) | LT3891156T (https=) |
| MA (1) | MA54379B1 (https=) |
| MD (1) | MD3891156T2 (https=) |
| MX (1) | MX2021006702A (https=) |
| PL (1) | PL3891156T3 (https=) |
| PT (1) | PT3891156T (https=) |
| RS (1) | RS65047B1 (https=) |
| SI (1) | SI3891156T1 (https=) |
| TW (1) | TWI905090B (https=) |
| WO (1) | WO2020115183A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015097123A1 (en) * | 2013-12-23 | 2015-07-02 | Les Laboratoires Servier | New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them |
| WO2016207225A1 (en) * | 2015-06-23 | 2016-12-29 | Les Laboratoires Servier | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3008975A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3046792B1 (fr) | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2019
- 2019-12-05 LT LTEPPCT/EP2019/083773T patent/LT3891156T/lt unknown
- 2019-12-05 FI FIEP19817229.8T patent/FI3891156T3/fi active
- 2019-12-05 RS RS20240001A patent/RS65047B1/sr unknown
- 2019-12-05 MX MX2021006702A patent/MX2021006702A/es unknown
- 2019-12-05 TW TW108144437A patent/TWI905090B/zh active
- 2019-12-05 CA CA3121363A patent/CA3121363A1/en active Pending
- 2019-12-05 PL PL19817229.8T patent/PL3891156T3/pl unknown
- 2019-12-05 SI SI201930704T patent/SI3891156T1/sl unknown
- 2019-12-05 DK DK19817229.8T patent/DK3891156T3/da active
- 2019-12-05 MD MDE20210991T patent/MD3891156T2/ro unknown
- 2019-12-05 US US17/295,521 patent/US12129261B2/en active Active
- 2019-12-05 WO PCT/EP2019/083773 patent/WO2020115183A1/en not_active Ceased
- 2019-12-05 PT PT198172298T patent/PT3891156T/pt unknown
- 2019-12-05 JP JP2021531796A patent/JP7649241B2/ja active Active
- 2019-12-05 AR ARP190103554A patent/AR117255A1/es unknown
- 2019-12-05 EP EP19817229.8A patent/EP3891156B1/en active Active
- 2019-12-05 MA MA54379A patent/MA54379B1/fr unknown
- 2019-12-05 IL IL283656A patent/IL283656B2/en unknown
- 2019-12-05 EA EA202191534A patent/EA202191534A1/ru unknown
- 2019-12-05 BR BR112021010072-5A patent/BR112021010072A2/pt unknown
- 2019-12-05 KR KR1020217020808A patent/KR102855345B1/ko active Active
- 2019-12-05 ES ES19817229T patent/ES2971258T3/es active Active
- 2019-12-05 CN CN201980080579.8A patent/CN113166169A/zh active Pending
- 2019-12-05 HU HUE19817229A patent/HUE065266T2/hu unknown
- 2019-12-05 AU AU2019391329A patent/AU2019391329B2/en active Active
- 2019-12-05 HR HRP20240211TT patent/HRP20240211T1/hr unknown
-
2024
- 2024-09-24 US US18/894,074 patent/US20250011337A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015097123A1 (en) * | 2013-12-23 | 2015-07-02 | Les Laboratoires Servier | New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them |
| WO2016207225A1 (en) * | 2015-06-23 | 2016-12-29 | Les Laboratoires Servier | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250011337A1 (en) | Crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them | |
| US20240417390A1 (en) | Hydrogen sulfate salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same | |
| EP3248983B1 (en) | Crystal form a of obeticholic acid and preparation method therefor | |
| CA3102848A1 (en) | Novel salts and crystals | |
| US10464946B2 (en) | Crystalline forms of thienopyrimidine compound | |
| RU2844681C2 (ru) | Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции | |
| RU2847971C2 (ru) | Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции | |
| EP2066677B1 (en) | Pyridooxazepine progesteron receptor modulators | |
| HK40060606B (en) | New crystalline forms of a thienopyrimidine as mcl-1 inhibitor | |
| HK40060606A (en) | New crystalline forms of a thienopyrimidine as mcl-1 inhibitor | |
| HK40057196A (en) | New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them | |
| EA044230B1 (ru) | Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции | |
| EA043392B1 (ru) | Новая соль ингибитора bcl-2, соответствующая кристаллическая форма, способ их получения и фармацевтические композиции, которые их содержат | |
| HK40060608B (en) | Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same | |
| HK40060608A (en) | Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same | |
| OA20227A (en) | Novel salt of A BCL-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same. | |
| WO2019134970A1 (en) | Novel salts of a bcl-2 inhibitor,related crystalline forms,method for preparing the same and pharmaceutical compositions containing the same | |
| HK1126767B (en) | Pyridooxazepine progesteron receptor modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |